Complex genotype-phenotype (🫀-🧬) relationship Challenges in linking specific variants to clinical outcomes: ➡️High genetic heterogeneity ➡️Phenocopies ➡️Genetic noise ➡️Impact of modifier genes, epigenetic, and environmental variables TNNT2⚡️risk MYBPC3 milder phenotypes

Now published online, these data are the first look at aficamten in non-obstructive HCM over a 36 week treatment period in the FOREST-HCM open-label trial. This is also the first look at 20 mg dose. Read the study here onlinelibrary.wiley.com/doi/10.1002/ej… Follow along #CardioTwitter

Los científicos también necesitan su tiempo para pensar, reflexionar y… beber café como si fuera la respuesta a todas las incógnitas del universo. ☕🔬💭 nature.com/articles/d4158…

⁦⁦The ISHLT⁩ program planning committee meeting in Atlanta- working hard to make sure that #ISHLT2025 will be wicked good! See you in Boston next April. ⁦ISHLT President⁩ ⁦Susie Newton⁩

5a relliscada de l’amic Raphinha. Aquest any si! FC Barcelona El Barça juga a RAC1

New development in chronic #HeartTx rejection. Leukotriene B4 is a key mediator of cardiac allograft vasculopathy (CAV), the leading cause of chronic rejection. Targeting leucotriene B4 could be a novel treatment option to prevent CAV. Dong Wang 🔗 jhltonline.org/article/S1053-…

Pleased to share our work “Prognostic Role of Tissue Iron Deficiency Measured by sTfR Levels in Heart Failure Patients without Systemic Iron Deficiency or Anemia”mdpi.com/2910124 #mdpijcm a través de MDPI IDIBELL Hospital Universitari Bellvitge | HUB

3 entradas prácticamente agresiones sin pelota de Thierry en 25 min. Otra a Lamine, sin tarjeta. El árbitro ni mu. El césped largo y seco. ¿Espectáculo? LALIGA

📢 The U.S. Centers for Medicare & Medicaid Services recently decided to reverse a proposal that would have restricted coverage for #cfDNA testing. The #ISHLTAdvocacyCommittee & others worked to ensure access to a tool transplant professionals use to detect & treat allograft

We are with you, Marc 💙❤️

Have you read the latest #ISHLT Guideline Document for the evaluation and care of #HeartTransplant candidates yet? 🔖🫀 Since the publication of the ISHLT guidelines in 2006 & the 10-year update in 2016, there have been significant changes to care.  The changes pertain to 3

#ESCCongress Exciting results from VAD WEAN Cardiac Recovery International Registry (>750 pts, >50 sites): a) multi-year durability of cardiac recovery equivalent to post-Transplant survival b) similarly favorable results for all HF etiologies. Wilfried Mullens Harriette Van Spall, MD MPH

Quo vadis… most important! Great job!

This is excellent Ahmad Masri 👏. Great job in depicting and pinpointing the most relevant of these results, and insights into the complexity of CMIs mechanistics in oHCM!! Very much will be seen in noHCM!? Looking forward to!! 👏👏👏👏

Enorme Carlin. Must read: lavanguardia.com/opinion/202409…

On behalf of our multicenter team we presented at #ESCCongress 2024: Multicenter Model to Determine the Individualized Probability of Myocardial Recovery: The RecoverHeart Calculator THANK YOU to the 7 participating sites and co-investigators (see picture)

El 27/09 l'ICCV organitza la III Jornada Sobre Cardiopaties Familiars i Síndromes Associats a Mort Sobtada Dirigida a personal que tracten pacients amb miocardiopaties primàries o malalties sistèmiques que poden provocar afectació miocàrdica. ℹ️i.mtr.cool/qrpflotfly